Latest News
KOL Event - 14 March 2022 at 11am ET
04 March 2022
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
01 March 2022
New York, March 1, 2022 - Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER...
Tiziana Life Science's Presentation at the Bio CEO & Investor Conference 2022
11 February 2022
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
10 February 2022
February 10, 2022, New York, NY – Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that Dr Kunwar Shailubhai, Chief Executive Officer and Chief...
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease
04 February 2022
- - Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study
New York, February 4, 2022 – Tiziana Life Sciences Ltd (Nasdaq: TLSA)...
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference
26 January 2022
NEW YORK – 26 January 2022 – Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational drug delivery technologies to enable alternative routes...